The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
 
Olatunji B. Alese
Consulting or Advisory Role - Purdue Pharma
Research Funding - Acetylon Pharmaceuticals; Bristol-Myers Squibb; Five Prime Therapeutics; Tesaro
 
Walid Labib Shaib
Research Funding - ArQule (Inst); Lilly (Inst)
 
Mehmet Akce
No Relationships to Disclose
 
Christina Wu
Honoraria - BioTheranostics
Research Funding - Amgen; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Vaccinex (Inst)
 
Bassel F. El-Rayes
Honoraria - Bayer; Lexicon; RTI Health Solutions
Consulting or Advisory Role - Bayer; BTG; Loxo; Merrimack; RTI Health Solutions
Speakers' Bureau - Bristol-Myers Squibb; Lexicon
Research Funding - AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PPD (Inst); Taiho Pharmaceutical (Inst)